Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tempest Therapeutics

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Extends Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Participate in Upcoming Investor Conferences
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Year End 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Adopts Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
From Tempest Therapeutics
Via GlobeNewswire
Tickers TPST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.